We are live on ! Find out more

756 hedge funds and large institutions have $16.3B invested in Sanofi in 2024 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 296 increasing their positions, 236 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 60

31% more call options, than puts

Call options by funds: $125M | Put options by funds: $95.4M

30% more funds holding in top 10

Funds holding in top 10: 1013 (+3)

25% more repeat investments, than reductions

Existing positions increased: 296 | Existing positions reduced: 236

23% more capital invested

Capital invested by funds: $13.2B → $16.3B (+$3.01B)

4% more funds holding

Funds holding: 728756 (+28)

0.74% more ownership

Funds ownership: 21.48%22.22% (+0.74%)

Holders
756
Holders Change
+28
Holders Change %
+3.85%
% of All Funds
10.86%
Holding in Top 10
13
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+30%
% of All Funds
0.19%
New
92
Increased
296
Reduced
236
Closed
60
Calls
$125M
Puts
$95.4M
Net Calls
+$29.4M
Net Calls Change
-$48.1M

SNY Hedge Fund Activity: Q3 2024 in Review

756 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q3 2024, worth a combined $16.3B — up 23% from $13.2B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new SNY positions and 60 closed out — a net gain of 32 holders — while 296 added to existing stakes and 236 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $210M. The largest seller was Fidelity Investments, cutting an estimated $356M.

  • 756 institutional investors held Sanofi (SNY) as of Q3 2024, up from 728 in Q2 2024.
  • Funds reported $16.3B of Sanofi stock for Q3 2024, up 23% quarter-over-quarter.
  • 92 funds opened new Sanofi positions in Q3 2024 and 60 closed out, a net change of +32 holders.
  • The largest Sanofi buyer in Q3 2024 was T. Rowe Price Associates, an estimated $210M added.
  • The largest Sanofi seller in Q3 2024 was Fidelity Investments, an estimated $356M sold.

Based on aggregated 13F filings for Q3 2024.